Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
A New Era for Multiple Sclerosis Disease-Modifying Therapy: EU5 Prescriber and Payer Perspectives on Current Mainstays, Recent Market Entrants, and Late-Stage Pipeline Products | Physician & Payer Forum | EU5 | 2014
By February 2014, European marketing authorizations were granted for three new disease-modifying therapies (DMTs) for the treatment of multiple sclerosis (MS)—Aubagio (Sanofi/Genzyme), Lemtrada (…
Hospital-Treated Infections (Access to Novel Antibiotics: How Are Payers and Physicians Shaping the Market?) | Physician & Payer Forum | China | 2014
The lackluster global antibiotics pipeline and surge of antibiotic resistance in clinical isolates in China have triggered a new quest for novel antibiotics against complicated HTI. Many local and…
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Relapsed/Refractory) | Decision Base | US | 2014
As the Relapsed/Refractory Treatment Setting for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Becomes More Crowded, What Key Attributes Will Differentiate Emerging Therapies According to…
Nephrology (Renal Anemia and Bone and Mineral Metabolism) | TreatmentTrends | US | Q1 2014
This quarterly report provides a detailed analysis of emerging and current therapies in nephrology based on responses from surveyed U.S. nephrologists. Emphasis is on anemia management (ESAs and IV…
Hypertriglyceridemia: Novel Agents Vascepa and Epanova Compete for Share of This Growing Dyslipidemia Subpopulation | Physician & Payer Forum | US | 2014
Hypertriglyceridemia (HTG) is defined as an abnormal concentration of triglyceride in the blood. Classification of serum triglyceride (TG) levels greater than 150 mg/dL as elevated is largely based…
Global Biosimilars Markets (Regulations, Pipelines and Major Players) | Biosimilars Advisory Service | US/EU5/Asia Pacific | 2014
The biosimilars market is not all about the United States, Europe, and Japan. Although these developed markets account for 80% of branded biologics sales, the rest-of-world segment includes many…
Methicillin-Resistant Staphylococcus Aureus Complicated Skin and Skin Structure Infections | Decision Base | US/EU | 2014
In The Crowded MRSA cSSSI Market, How Will Emerging Therapies Differentiate Themselves from Current Standard of Care? Methicillin-resistant Staphylococcus aureus (MRSA) is a clinically important…
Methicillin-Resistant Staphylococcus Aureus Complicated Skin and Skin Structure Infections | Decision Base | US | 2014
In The Crowded MRSA cSSSI Market, How Will Emerging Therapies Differentiate Themselves from Current Standard of Care? Methicillin-resistant Staphylococcus aureus (MRSA) is a clinically important…
